Skandinaviska Enskilda Banken (SEB)’s Ascendis Pharma A/S ASND Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,990	Closed	-$8.31M	–	206
2025 Q4	$8.31M	Buy	38,990 +10,223	+36%	+$2.11M	0.03%	316
2025 Q3	$5.72M	Buy	+28,767	New	+$5.37M	0.02%	394
2022 Q3	–	Sell	-193	Closed	-$18K	–	900
2022 Q2	$18K	Hold	193	–	–	﹤0.01%	989
2022 Q1	$23K	Hold	193	–	–	﹤0.01%	970
2021 Q4	$26K	Hold	193	–	–	﹤0.01%	967
2021 Q3	$31K	Buy	+193	New	+$26.4K	﹤0.01%	987

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ASND Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 38,990 shares — an estimated $8.31M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ASND in Q3 2021 and held it in 6 quarters. The position peaked at $8.31M in Q4 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 38,990 Ascendis Pharma A/S shares in Q1 2026, an estimated $8.31M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Ascendis Pharma A/S in Q3 2021 and held it in 6 quarters.
Skandinaviska Enskilda Banken (SEB)'s Ascendis Pharma A/S position peaked at $8.31M in Q4 2025.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.